Conor launches countersuit against Angiotech:
This article was originally published in Clinica
Conor Medsystems, the Nasdaq-listed, Menlo Park, California-based developer of drug-eluting stents, has launched legal proceedings in the UK against Canadian firm Angiotech Pharmaceuticals. Conor wants the court to revoke Angiotech's European patent relating to stents coated with paclitaxel and a polymer carrier. Its challenge follows Angiotech's filing of a joint lawsuit with DES partner Boston Scientific against Conor earlier this month, accusing the latter of infringing the patent in question. Vancouver-based Angiotech said it expected Conor to "take various defensive acts", against which it would defend itself "to the fullest".
You may also be interested in...
Tensions between industry and the European Commission on the issue of health claims for botanical food supplements were aired on the second day of the BAH's High Level Conference on the Future of Medicines, with the EC saying the EU Green Deal is now higher up on its list of priorities for the foreseeable future.
Issues over supply and the use of a skinny label have the potential to take a toll on the market for the fish oil drug icosapent ethyl, one analyst has claimed in the wake of Hikma’s recent generic launch.
The German Bundestag has adopted the Unified Patent Court’s draft ratification bill with the necessary qualified majority.